VRTX

Over the past six months (November 2025 to May 2026), VRTX stock has experienced fluctuations, with a 52-week high of $507.92 on March 10, 2026, and a 52-week low of $362.50 on August 11, 2025. As of May 8, 2026, the closing price was $429.82. In Q1 2026, Vertex reported total revenue of $2.99 billion, an 8% increase year-over-year, but slightly below Wall Street estimates, with non-GAAP EPS at $4.47, beating estimates, leading to a 1.1% decline in VRTX shares. The commercialization of CASGEVY and JOURNAVX contributed to revenue growth, with these non-CF products delivering over 25% of the growth in Q1 2026, and ALYFTREK surpassed $1 billion in cumulative global revenue since its U.S. approval in December 2024, with label expansions for ALYFTREK and TRIKAFTA covering approximately 95% of U.S. CF patients. Vertex completed the rolling Biologics License Application (BLA) submission for U.S. accelerated approval of povetacicept in IgA nephropathy in March 2026, following positive Phase 3 interim analysis data, but discontinued the Phase 1/2 study of VX-522, an mRNA therapeutic for CF, due to persistent tolerability issues related to lung inflammation.